Skip to main content

Meitheal gets FDA nod for insulin biosimilar

Pharmaceuticals
(Bloomberg)
August 03, 2026 05:15 AM CDT

Meitheal Pharmaceuticals will commercialize the U.S. rollout of newly FDA-approved Garzulys, an insulin biosimilar to Novolog, broadening its biologics and branded products business.

You must be a Health Pulse subscriber to access this content.

To read this article and get unlimited access to our website, subscribe now.
Health Pulse - Annual$399 for 1 year, renews automatically

Recommended For You